

Julian Musa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6768370/publications.pdf>

Version: 2024-02-01

20
papers

793
citations

759233

12
h-index

713466

21
g-index

31
all docs

31
docs citations

31
times ranked

1430
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma. <i>Molecular Cancer</i> , 2022, 21, 1.	19.2	25
2	Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation. <i>Cell Death Discovery</i> , 2022, 8, 91.	4.7	6
3	Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. <i>Molecular Cancer</i> , 2021, 20, 97.	19.2	24
4	Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. <i>Nature Communications</i> , 2021, 12, 5356.	12.8	11
5	Proliferation Assessment by Trypan Blue Exclusion in Ewing Sarcoma. <i>Methods in Molecular Biology</i> , 2021, 2226, 151-158.	0.9	6
6	Drug Screening by Resazurin Colorimetry in Ewing Sarcoma. <i>Methods in Molecular Biology</i> , 2021, 2226, 159-166.	0.9	3
7	Integrative clinical transcriptome analysis reveals <i>TMPRSS2</i> dependency of prognostic biomarkers in prostate adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 146, 2036-2046.	5.1	13
8	Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1682924.	0.7	6
9	Sarcoma treatment in the era of molecular medicine. <i>EMBO Molecular Medicine</i> , 2020, 12, e11131.	6.9	154
10	Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma. <i>Nature Communications</i> , 2020, 11, 2423.	12.8	35
11	High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 644.	3.7	16
12	Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients. <i>EBioMedicine</i> , 2019, 47, 156-162.	6.1	23
13	Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. <i>Nature Communications</i> , 2019, 10, 4128.	12.8	51
14	Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma. <i>Cell Death and Disease</i> , 2019, 10, 116.	6.3	23
15	Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2019, 144, 859-867.	5.1	10
16	Hepatitis B virus large surface protein is priming for hepatocellular carcinoma development via induction of cytokinesis failure. <i>Journal of Pathology</i> , 2019, 247, 6-8.	4.5	15
17	PRC1: Linking Cytokinesis, Chromosomal Instability, and Cancer Evolution. <i>Trends in Cancer</i> , 2018, 4, 59-73.	7.4	59
18	Systematic identification of cancer-specific MHC-binding peptides with RAVEN. <i>Oncolmmunology</i> , 2018, 7, e1481558.	4.6	16

#	ARTICLE	IF	CITATIONS
19	Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. <i>Oncotarget</i> , 2018, 9, 1587-1601.	1.8	66
20	MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. <i>Cell Death and Disease</i> , 2017, 8, e2895-e2895.	6.3	226